Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METATENSIN #4 vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing c GMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Hypertension
Hypertension
2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
12-18 hours; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min)
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Reserpine: extensively metabolized in liver via unidentified pathways; Hydralazine: N-acetylation (polymorphic NAT2), also hydroxylation and glucuronidation; Hydrochlorothiazide: not significantly metabolized, excreted unchanged in urine.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Renal (70% unchanged, 20% as metabolites); biliary/fecal (10%)
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
95% bound to albumin and alpha-1-acid glycoprotein
Approximately 70-80% bound to plasma proteins, primarily albumin.
0.5-1.0 L/kg; indicates moderate tissue distribution
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: 60-80% (first-pass metabolism reduces from 100%)
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
No dosage adjustment required for renal impairment.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Severe hepatic impairment (Child-Pugh class C): Use with caution; reduce dose or prolong interval. Child-Pugh class A or B: No adjustment necessary.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not established; safety and efficacy in children have not been studied.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Elderly patients may be more sensitive to hypotensive effects; initiate at lower dose (1 tablet) and titrate carefully.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None.
None.
Reserpine: mental depression, peptic ulcer, ulcerative colitis. Hydralazine: drug-induced lupus erythematosus, peripheral neuritis. Hydrochlorothiazide: electrolyte disturbances, hyperuricemia, acute angle-closure glaucoma, sulfonamide allergy cross-reactivity.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Reserpine: history of depression, active peptic ulcer, ulcerative colitis, pheochromocytoma, electroconvulsive therapy. Hydralazine: hypersensitivity, coronary artery disease, mitral valvular rheumatic heart disease. Hydrochlorothiazide: anuria, hypersensitivity to sulfonamide-derived drugs.
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid high-potassium foods (bananas, oranges, salt substitutes) due to risk of hyperkalemia with methyldopa. Limit sodium intake for antihypertensive effect. Alcohol may potentiate orthostatic hypotension and sedation.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
METATENSIN #4 (combination of hydrochlorothiazide 50 mg and methyldopa 250 mg per tablet) carries teratogenic risks primarily due to hydrochlorothiazide. First trimester: Thiazide diuretics are associated with a small increased risk of neural tube defects and cardiovascular anomalies; however, methyldopa is considered low risk for major malformations. Second trimester: Use may cause fetal electrolyte disturbances and thrombocytopenia. Third trimester: Thiazides can cause neonatal hypotension, hypoglycemia, bone marrow suppression, and volume depletion; methyldopa is associated with neonatal bradycardia and hypotension. Overall risk is considered moderate; alternative antihypertensives are preferred, especially in the first trimester.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Hydrochlorothiazide is excreted into breast milk in low concentrations (M/P ratio ~0.3), but its use may suppress lactation. Methyldopa is excreted into breast milk with M/P ratio approximately 0.3-0.5; infant exposure is low but may cause bradycardia or sedation. The combination should be used with caution during breastfeeding; monitoring the infant for signs of hypotension, electrolyte imbalance, and sedation is recommended.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
During pregnancy, the pharmacokinetics of methyldopa and hydrochlorothiazide may be altered due to increased plasma volume and renal blood flow. Initial dosing should be based on maternal weight. Methyldopa: Dose may need to be increased in second and third trimesters due to increased clearance; maximum dose 2 g/day. Hydrochlorothiazide: Avoid use in pregnancy due to risks; if absolutely necessary, dose should be minimized. Dose adjustments should be guided by maternal blood pressure response and fetal well-being.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Metatensin #4 is a combination of thiazide diuretic (hydrochlorothiazide 50 mg) and central alpha-agonist (methyldopa 500 mg). Use with caution in patients with renal impairment; monitor serum creatinine and electrolytes. Avoid abrupt discontinuation (risk of rebound hypertension). May cause positive Coombs test and hemolytic anemia (rare). Dose adjustment required in renal failure (Cr Cl <30 m L/min).
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how you react.,Rise slowly from sitting or lying positions to prevent dizziness.,Avoid excessive sweating or dehydration; drink adequate fluids unless fluid-restricted.,Report unusual tiredness, fever, dark urine, yellowing of eyes/skin, or easy bruising/bleeding.,May increase blood sugar; monitor if diabetic.,Avoid alcohol, which can increase dizziness and drowsiness.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METATENSIN #4 vs ALDOCLOR-150, answered by our medical review team.
METATENSIN #4 is a Antihypertensive Combination that works by Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing c GMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METATENSIN #4 and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METATENSIN #4 is: 2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METATENSIN #4 and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METATENSIN #4 is classified as Category C. METATENSIN #4 (combination of hydrochlorothiazide 50 mg and methyldopa 250 mg per tablet) carries teratogenic risks primarily due to hydrochlorothiazide. First trimester: Thiazide . ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.